Clinical Trial Update: A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder [Phase 1]

View source ↗

Summary

This Phase 1 safety and pharmacokinetic study evaluated the extended-release osmotic-release (ER OROS) formulation of paliperidone in pediatric patients with sc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia
• Schizophreniform Disorder

Drugs mentioned

• ER OROS Paliperidone (paliperidone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 1 | Status: COMPLETED